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Coupling of PARP1-mediated chromatin 
structural changes to transcriptional RNA 
polymerase II elongation and cotranscriptional 
splicing
Elena A. Matveeva1, Qamar M. H. Al‑Tinawi1,2, Eric C. Rouchka3,4 and Yvonne N. Fondufe‑Mittendorf1* 
Abstract 
Background: Recently, we showed that PARP1 is involved in cotranscriptional splicing, possibly by bridging chroma‑
tin to RNA and recruiting splicing factors. It also can influence alternative splicing decisions through the regulation of 
RNAPII elongation. In this study, we investigated the effect of PARP1‑mediated chromatin changes on RNAPII move‑
ment, during transcription and alternative splicing.
Results: We show that RNAPII pauses at PARP1–chromatin structures within the gene body. Knockdown of PARP1 
abolishes this RNAPII pausing, suggesting that PARP1 may regulate RNAPII elongation. Additionally, PARP1 alters 
nucleosome deposition and histone post‑translational modifications at specific exon–intron boundaries, thereby 
affecting RNAPII movement. Lastly, genome‑wide analyses confirmed that PARP1 influences changes in RNAPII elon‑
gation by either reducing or increasing the rate of RNAPII elongation depending on the chromatin context.
Conclusions: These studies suggest a context‑specific effect of PARP1–chromatin binding on RNA polymerase 
movement and provide a platform to delineate PARP1’s role in RNA biogenesis and processing.
Keywords: Splicing, RNA polymerase II, Epigenetics, Poly(ADP)ribose polymerase, Polymerase elongation, 
Nucleosomes, Chromatin
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Introduction
PARP1 also known as ARDT1 belongs to family of pro-
teins known as ADP-ribosylases. This group of enzymes, 
up to 17 in humans, have varying degrees of homology 
but a highly conserved PARP catalytic domain. These 
proteins use NAD+ as a substrate to catalyze the addi-
tion of ADP-ribose moiety(ies) onto target proteins, 
hence the name ADP-ribosyltransferase. Within this 
family, only PARP1 and PARP2 can build “poly”-ADP-
ribose polymers, while the others are capable of adding 
only a monomeric ADP-ribose to proteins.
PARP1 is the most studied of this family of proteins for 
which multiple functions been described, which implies 
pleiotropic functional characteristics. PARP1 is well 
known for its role in DNA-repair, genome integrity, and 
cell death [1]. It also adds poly-ADP-ribose (PAR) onto 
several proteins involved in NAD+ metabolism [2]. 
Additionally, for innate immunity, DNA damage, or met-
abolic stress, PARP1 can act as a coactivator of NF-κB 
transcription factors, contributing to the transcription of 
a subset of NF-κB target genes [3]. Increasingly, the role 
of PARP1 in modulating chromatin structure to regulate 
gene expression is being recognized. PARP1 adds PAR 
residues (PARylates) onto histones [4], which opens the 
chromatin structure and enables gene activation. In sup-
port of this function of maintaining active transcription, 
several genome-wide studies show PARP1 to be associ-
ated with active gene promoters [5, 6], and competing 
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with the repressive histone H1 [7, 8] to elicit differential 
gene expression outcomes. However, while it is clear 
that PARP1 is important in gene activation, other studies 
have shown that depletion of PARP1 also results in gene 
repression [7–11], suggesting that PARP1 most likely acts 
in a context-specific manner.
Regulation of gene expression occurs at both the tran-
scriptional initiation and splicing levels, with chromatin 
structure influencing both processes. Interestingly, while 
the role of chromatin in transcription has been stud-
ied significantly, the role of chromatin in splicing is just 
emerging. The recent discovery that splicing, or the deci-
sion of a particular region to be spliced, occurs cotran-
scriptionally while the nascent mRNA is still tethered to 
chromatin, developed into the cotranscriptional splicing 
hypothesis [12–14]. Indeed, changes to the epigenome 
that mediate chromatin structural integrity have been 
implicated in alternative splicing regulation. For instance, 
DNA methylation and histone modifications demarcate 
exon–intron boundaries [13, 15–19] that regulate splic-
ing decisions. It is, therefore, possible that in regulating 
chromatin structure, PARP1 might also play a role in this 
process. Indeed, our previous study demonstrated a func-
tional role for PARP1 and PARylation in the regulation of 
pre-mRNA splicing [5]. We showed that PARP1 binds to 
nucleosomes at target exon/intron boundaries, mediating 
specific splicing decisions. In addition, we demonstrated 
that knockdown of PARP1 or inhibition of its PARylation 
activity resulted in changes in specific alternative splic-
ing patterns. Interestingly, splicing products in PARP1 
knockdown (KD) cells versus PARylation-inhibited cells 
were not similar, possibly suggesting that the effects of 
PARP1 on chromatin binding are direct while its PARyla-
tion activity is indirect. We therefore hypothesized that 
modulation of chromatin structure by PARP1 directly 
affects splicing decisions, while its PARylation activity 
could regulate splicing through activation of splicing fac-
tors [20] and/or through PARylation of histones [1, 21, 
22] to open up the chromatin structure. However, a clear 
understanding of how PARP1 regulates alternative splic-
ing is unknown.
Two non-mutually exclusive models have been hypoth-
esized to explain how chromatin structure or factors 
that modulate chromatin structure, regulate alternative 
splicing. (1) The kinetic model proposes that chromatin 
structure regulates the speed of polymerase elongation 
to influence splicing outcomes [23]. (2) The adaptor/
recruitment model proposes that chromatin or its asso-
ciated factors recruit splicing factors, bridging the chro-
matin structure and the nascent mRNA [24–26]. PARP1 
could act in both models: PARP1–chromatin binding 
is well established, and in addition to this function, we 
showed that PARP1–chromatin binds to splicing factor 
3B1 (SF3B1), a U2 spliceosomal member [5], and might 
therefore act as an adapter, bringing the splicing com-
plex (with SF3B1) to RNA. As a further step, we showed 
that PARP1 binds RNA and identified the PARP1-mRNA 
binding landscape [11]. In summary, these data support 
the adapter model for PARP1 to regulate splicing. How-
ever, it is not implausible that PARP1 also could regulate 
the rate of polymerase elongation, especially as PARP1 
has been shown to be involved in polymerase pausing 
at the promoters of heat shock genes [27]. We therefore 
hypothesized that if PARP1 plays a role in polymerase 
pausing at the transcription level (promoter region), it 
may also play a role in chromatin structure that pauses 
RNAPII elongation along the gene body for splicing regu-
lation. In the current study, we propose that PARP1 also 
works as an RNAPII regulator through mutual interde-
pendence of splicing and transcription elongation. Using 
S2 Drosophila cells as a convenient model (Drosophila 
contains only one PARP1 gene), we tested the effect of 
PARP1 on the RNAPII elongation rate and cotranscrip-
tional splicing.
Results
PARP1 is involved in mRNA splicing
We previously showed that PARP1 KD in Drosophila S2 
cells results in changes in alternative splicing of several 
genes [5]. Our goal in this study is to understand mecha-
nistically how PARP1 modulates chromatin structure 
to regulate splicing decisions. We chose to analyze this 
mechanism in depth at two genes—AKAP200 (hence 
called AKAP) and CAPER—because we found that (1) 
PARP1 binds to nucleosomes within their gene bodies 
and (2) PARP1 depletion correlated with changes in the 
splicing decisions observed through RNA-seq genome-
wide analyses [5] (Fig.  1a). We used RNA interference 
to deplete PARP1 in S2 Drosophila cell lines (Additional 
file 1: Fig. S1), to assess whether PARP1 binding on AKAP 
and CAPER exon–introns reflects a direct role for PARP1 
in alternative splicing decisions at these genes. We then 
performed PCR with exon junction spanning primers to 
validate the splicing changes (Fig. 1b). These results val-
idated the genome-wide studies [5] and showed that in 
the absence of PARP1, differentially spliced transcripts 
for AKAP and CAPER were produced. Furthermore, 
a second siRNA (siRNA2) targeting a different region 
of PARP1 (Additional file  1: Fig.  S1A and B) confirmed 
these results (Additional file 1: Fig. S2). To test whether 
this effect is due to PARP1 directly or its enzymatic activ-
ity, we inhibited its PARylation using PJ34 (Additional 
file  1: Fig.  S1C) and showed that PARylation inhibition 
effected no changes in splicing at these two target genes 
(Additional file 1: Fig. S2).
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PARP1–chromatin structure influences RNA polymerase 
elongation
We next tested whether PARP1 regulates splicing 
through regulation of the rate of RNAPII elongation. For 
this, we used our genome-wide data of PARP1 nucleo-
some occupancy (GSE56120) in Drosophila S2 cells 
with PRO-seq data [28] (GSE42117) of transcriptionally 
engaged RNA polymerase. Analyses of these binding 
profiles showed that PARP1 and engaged RNAPII are in 
close proximity within gene bodies. Indeed, we observe 
a shift ~ 25  bp downstream of the PARP1 signal relative 
to the RNAPII signal (shown as metagene plots in Addi-
tional file 1: Fig. S3). These data suggest that PARP1 may 
be involved in RNAPII elongation stalling. Next, we 
investigated if these binding profiles are true in our genes 
of interest above.
The processivity of RNAPII depends on the phospho-
rylation state of its carboxy terminal domain (CTD). 
In particular, the transition between initiation-pausing 
and productive elongation is marked by phosphoryla-
tion on Ser5 and Ser2, respectively [29–31]. We there-
fore asked whether PARP1 influences the recruitment 
of different forms of phosphorylated RNAPII to exonic 
regions of our target genes, AKAP and CAPER. Three 
antibodies that bind specific phosphorylation states 
of RNAPII were used: (1) 4H8, which recognizes Ser5 
phosphorylation (marks initiating and first regions of 
the gene)—hence referred to as Ser5; (2) H5, which rec-
ognizes Ser2 phosphorylation is found mainly in the 
gene body and toward the 3′ end of the gene. This form 
is known as the transcriptionally engaged and elon-
gating form of RNAPII—hence referred to as Ser2P; 
(3) 8WG16, which recognizes hypo-phosphorylated 
a
b
Fig. 1 PARP1 depletion alters splicing decisions. a Sashimi plots showing changes in the splicing decisions due to PARP1 depletion in RNA‑seq 
genome‑wide analyses for AKAP200 and CAPER. b PCR products with exon junction spanning primers validate splicing changes in AKAP200 and 
CAPER. Agarose gel images and percentage of exons inclusion show the difference in splicing product between non‑treated (WT) and PARP1 
knockdown (KD) cells. Actin is shown as a PARP1 non‑target gene. Additionally, the percentage of each isoform included is calculated as a 
percentage of all transcripts amplified by PCR set to a 100%
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RNAPII found at pre-initiation sites. The 8WG16 anti-
body has been reported to sometimes also recognize 
Ser5-phosphorylated RNAPII and could be used to 
determine total RNAPII. We therefore performed ChIP-
qPCR using these antibodies on cross-linked chroma-
tin from wild type (WT) and PARP1 knockdown (KD) 
cells and analyzed the occupancy of the various forms 
of RNAPII on the two PARP1 target genes—AKAP and 
CAPER (Fig. 2 and Additional file 1: Fig: S4). To better 
assess the correlation between PARP1 reduction and 
RNAPII occupancy, we calculated the ratio between the 
occupancies of these polymerase forms and PARP1 at 
three locations: (1) the immediate preceding constitu-
tive exon; (2) the intervening intron; (3) the proceed-
ing alternative exon of these genes as shown in Fig. 2a. 
We call this the ‘travelled’ index as it determines the 
ratio of PARP1 (or RNAPII) occupancy at the proceed-
ing intron or alternative exon, relative to the preceding 
constitutive exon.
To begin, the occupancy of PARP1 was measured. In 
WT cells, at the AKAP gene, a 22% reduction in the rela-
tive occupancy of PARP1 was observed at the alternative 
a
b c
d e
Fig. 2 PARP1 and RNAPII ChIP‑qPCR for PARP1 target genes AKAP200 and CAPER. a Diagram of constitutive (black boxes) and alternative (gray 
boxes) exons of a wider region (upper) and zoomed in region (lower) for AKAP200 and CAPER genes. Green arrows depict primer locations. b, c 
Showing the relative occupancy of PARP1 in wild type (WT, blue line) and PARP1 knockdown (KD, red line) cells for AKAP200 and CAPER at the 
alternative exon relative to presiding constitutive exon. d, e Showing RNAPII occupancy (elongation form, Ser2P) for AKAP200 and CAPER. All 
experiments were performed in triplicate, and results are presented as mean ± SD (*p value < 0.05). Statistical significance was tested by Student’s t 
test method
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exon 5 compared to constitutive exon 4 (Fig.  2b and 
Additional file  1: Fig.  S4A—blue bar). When using the 
‘travelled’ index, this represented a steady decline of 
PARP1 occupancy from the 5′ constitutive exon 4 to pro-
ceeding intron 4–5 and was lowest at the 3′ alternative 
exon 5 (Fig.  2b). In PARP1 depleted conditions (PARP1 
KD cells), a reduction of ~ 80% of PARP1 occupancy was 
measured at alternative exon 5 relative to constitutive 
exon 4 (Additional file  1: Fig.  S4A—red bar). With the 
travelled index incorporated, this change represented a 
further decrease of ~ 45% and ~ 80% in PARP1 occupancy 
at the proceeding intron 4–5 and at alternative exon 
5 relative to the constitutive exon (Fig.  4b—red line). A 
similar trend was observed at the CAPER gene though 
the decrease in the relative amount of PARP1 occu-
pancy from constitutive exon 3 to alternative exon 4 was 
less pronounced. As expected, there was an additional 
decrease in PARP1 occupancy at all the tested sites in KD 
cells (Fig. 2c and Additional file 1: Fig. S4A).
Next, we asked whether the observed changes in PARP1 
occupancy correlate with changes in the occupancy of 
RNAPII forms. Using the Ser2P antibody, which recog-
nizes the transcriptionally engaged, elongating form of 
RNAPII, we showed that depletion of PARP1 correlated 
with depletion of this transcriptionally engaged RNAPII 
at the studied exons. These data corroborated our directly 
measured results comparing alternative versus consti-
tutive exons and also those measured by the travelled 
index. In WT cells, as measured through direct compari-
son of occupancy at alternative exon versus constitutive 
exon, the AKAP gene showed a decrease of ~ 20% (Addi-
tional file  1: Fig.  S4B). Further supporting these data, 
the travelled index (Fig.  2d) showed a steady decline of 
Ser2P from the 5′ constitutive exon toward the 3′ alterna-
tive exon. These results were very similar for the CAPER 
gene (Fig.  2e and Additional file  1: Fig.  S4B). Interest-
ingly, in PARP1 knockdown cells, Ser2P decreased even 
further (~ 40% at intron 4–5 and alternative exon 5 
compared to constitutive exon 4 at AKAP) (Fig.  2d and 
Additional file 1: Fig. S4B), while this decrease in Ser2P 
was ~ 50% at CAPER gene regions (Fig.  2e and Addi-
tional file 1: Fig. S4B). These findings correlated with the 
observed decrease in PARP1 occupancy at these sites 
(Fig. 2b, c; Additional file 1: Fig. S4A). Next, we asked if 
this correlation of PARP1 occupancy is specific for only 
the elongating Ser2P occupancy. For this, we tested 
the occupancy of the other phosphorylated forms of 
RNAPII—the pre-initiating form of RNAPII, also known 
as hypo-phosphorylated RNAPII (8WG16), and Ser 5 
(4H8). In WT cells, the occupancy of 8WG16 at alterna-
tive exons over constitutive exons was reduced by 50% 
for both AKAP and CAPER genes, respectively (Addi-
tional file 1: Fig. S4C—blue bars). On the other hand, in 
KD cells, we observed an increase in the presence of this 
polymerase form (Additional file 1: Fig. S4C—red bars). 
Profiling of 4H8, which measures Ser5 which is found 
at TSSs and gene bodies, showed a slight increase at the 
alternative exon 5 of AKAP compared to the constitutive 
exon 4. For CAPER, we observed a large and significant 
decrease of ~ 80% occupancy of Ser5 (Additional file  1: 
Fig.  S4D—blue bars). In KD cells, AKAP exhibited an 
increase in this polymerase form while CAPER showed 
no significant difference in occupancy compared to WT 
cells (Additional file 1: Fig. S4D—red bars). Finally, analy-
sis of the occupancies of PARP1 and the various RNAPII 
were recapitulated in cells treated with a second siRNA 
(siRNA2), thus confirming the effect of PARP1 on the 
occupancy of RNAPII. In contrast, inhibition of PARyla-
tion showed no differences in PARP1 or in the occupan-
cies of the different RNAPII forms when compared to 
WT cells (Additional file  1: Fig.  S5). These data there-
fore show that PARP1 occupancy and not its PARylation 
activity exerts an effect on the occupancy of elongating 
polymerase.
PARP1 depletion disrupts chromatin state and structure
Chromatin context can affect the rate of RNAPII elonga-
tion, which in turn, would regulate alternative splicing. 
After confirming the relationship between PARP1 and 
RNAPII pausing, we next investigated the type of chro-
matin context mediated by PARP1 at these alternative 
exon sites. For this, we mapped the nucleosomes across 
AKAP and CAPER genes using the nucleosome walk-
ing method [32]—a low-resolution technique, which 
allows gene-specific high-resolution mapping of nucleo-
some positions along a stretch of DNA [33]. Chroma-
tin is digested with micrococcal nuclease (MNase) to 
yield mostly mononucleosomal fragments and is then 
subjected to quantitative real-time PCR (qRT-PCR—
see Methods). First, we predicted nucleosome loca-
tions based on sequences alone [34] (Fig.  3a, b—top 
panels). Then, primers were designed to amplify about 
80–100-bp-sized amplicons that overlapped by 20–40 bp, 
tiling across the selected loci of the AKAP and CAPER 
genes. In this technique, amplification of a product indi-
cates the presence of a protected mononucleosome, 
while the lack of amplification signifies open chromatin 
susceptible to MNase digestion. Nucleosome positions 
and strength of nucleosome occupancy were then calcu-
lated using the fold change between MNase-treated sam-
ples and undigested genomic DNA at an equivalent DNA 
input concentration (see Methods).
Based on this method, stable and highly reproducible 
profiles of nucleosomes were observed across the target 
gene region (Fig. 3), with clear differences in the nucleo-
some profile between WT and PARP1 KD cells. For the 
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AKAP gene, two clear observations were made: (1) There 
is a strong nucleosome in PARP1 KD cells, mapped by 
primer A8, which was previously absent in WT cells. 
(2) At the genomic locations mapped by primers A13 to 
A15, a reduction in nucleosome occupancy in PARP1 KD 
cells was seen, with a shift of the nucleosomes toward the 
A16 position (Fig. 3a). For the CAPER gene, we observed 
a reduction in nucleosome occupancy just before the 
alternate exon 4 (mapped by primers C8–C10) and in 
the region containing the alternative exon 4 (mapped by 
primers C12–C16) (Fig.  3b). Here too, PARP1 knock-
down using siRNA2 produced similar results for nucle-
osome repositioning as seen in cells transfected with 
PARP1 siRNA1, while PARylation-inhibited cells exhib-
ited no changes in nucleosome positioning when com-
pared to WT cells (Additional file 1: Fig. S6). Since these 
PARP1-mediated nucleosome rearrangements occur 
right before the alternate exon, we posit that PARP1 
maintains a chromatin structure that would be amenable 
to transcription elongation by RNAPII in the absence of 
PARP1.
PARP1 occupancy displays interplay of selective 
acquisition of histone methylation at genic regions
Several histone marks have been implicated in alterna-
tive splicing [20]. Given that our previous data showed 
interplay between PARP1 and certain histone marks 
[5], we then sought to determine whether interplay of 
PARP1 with specific histones could drive the observed 
chromatin rearrangement and transcriptional elonga-
tion machinery at the studied regions. Typically, paused 
gene regions are marked by bivalent histone marks. In 
view of this, we used ChIP-qRT-PCR, to measure the 
occupancy for both the activating mark, H3K4me3, and 
repressive mark, H3K27me3, in regions that showed the 
most change in nucleosome structure—regions mapped 
by primers A14 for AKAP and C8 for CAPER and its 
surrounding exons (Fig.  3). In WT cells, at both genes, 
H3K4me3 and H3K27me3 were found at all sites tested 
(preceding constitutive exon, intervening intron, and 
alternative exon) with varying levels (Fig.  4). The pres-
ence of both the activating H3K4me3 and repressive 
mark H3K27me3 is indicative of a poised gene region. To 
further assess whether there is interplay between these 
histone marks and PARP1, we investigated whether their 
occupancy is changed in the absence of PARP1. Knock-
down of PARP1 resolved this bivalency of H3K4me3 and 
H3K27me3 marks to H3K4me3. At both of these genes, 
there was an increase in H3K4me3 occupancy (Fig. 4a for 
AKAP and 4c for CAPER) and a decrease in H3K27me3 
occupancy (Fig.  4b for AKAP and 4D for CAPER). The 
resultant net gain of H3K4me3—an active histone 
mark—possibly opens up the chromatin structure allow-
ing for the passage of transcription machinery. These 
data were recapitulated in cells treated with siRNA2 
(Additional file 1: Fig. S7—red bars vs. blue bars), while 
PARylation-inhibited cells showed no difference relative 
to WT cells (Additional file 1: Fig. S7—green bars vs. blue 
bars). In summary, our data are consistent with a model 
in which binding of the PARP1 mediates or is mediated 
by specific histone modifications. Additionally, the effect 
of PARP1 on chromatin structure (nucleosome position-
ing and occupancy of histone PTMs) is instigated by the 
direct presence of PARP1 and not its PARylation activity. 
Thus, at the sites of alternative splicing, PARP1 could play 
a dual role in stimulating the release of RNAPII pausing 
and recruiting chromatin modifications that facilitate its 
release from the paused state.
PARP1 influences RNAPII elongation genome‑wide
The observations of the direct effect of PARP1 binding on 
chromatin structure and histone modification occupancy 
prompted us to ask whether PARP1 could influence the 
release of RNAPII from pause sites. We used a modified 
3′NT-seq method [35] and the NET-seq method [36] to 
map the positions of elongating and arrested RNAPII 
complexes at nucleotide resolution (Fig. 5a) in the pres-
ence and absence of PARP1. The 3′NT method effectively 
isolates mRNA from RNA-RNAPII–chromatin com-
plexes. The presence of the m7G cap on RNAPII tran-
scripts within the first 20–30 nucleotides of transcription 
allows for the immunoprecipitation of nascent mRNAs 
using the GFP-elF4E protein (which binds to the m7G 
cap) bound on magnetic beads. These captured mRNAs 
were then eluted from beads, purified, and ligated to the 
3′ adapter used in Illumina sequencing. Next, the RNAs 
were fragmented to not only decap the captured 5′ ends 
of the mRNAs, but also to reduce the size of the mRNAs 
(See figure on next page.)
Fig. 3 Analysis of nucleosome architecture. The positions of nucleosomes in non‑treated cells (WT, blue line) versus PARP1 knockdown (KD, red 
line) for the AKAP200 (a) and CAPER (b) genes are distinctive. For each gene, the top panel shows gene region and the predicted nucleosome 
location (gray ovals) based on sequence alone [34]. The bottom panel demonstrates the nucleosome position and occupancy (green ovals) 
obtained by nucleosome scanning analysis (see Methods). Depletion of PARP1 shifts nucleosome positioning and occupancy. Light green ovals 
depict reduction in nucleosome occupancy, while fuzzy nucleosomes are represented as nucleosomes overlying each other. All experiments 
were done in triplicate, and results are presented as mean ± SD (results were considered significant as determined by Student’s t test method: p 
value < 0.05)
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b
a
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to ~ 35–100 nucleotides. Fragmented mRNAs were then 
size selected on a denaturing gel. Next, the 5′ phos-
phate groups were removed enzymatically, allowing for 
the ligation of the 5′ sequencing adapter. cDNA librar-
ies were then prepared, and limited PCR amplification 
with primers that bind to both the 5′ and 3′ adapters was 
performed. This allowed for the capture and sequenc-
ing of only mRNA fragments with both the 5′ end (end 
after fragmentation) and the original 3′ end of the nas-
cent mRNAs. After PCR, samples were size selected on a 
3.3% NuSieve agarose gel. These fragments were treated 
and analyzed separately, gel purified, and subjected to 
Illumina high-throughput 50 bp paired-end sequencing. 
Two biological replicates for WT and PARP1-KD cells 
were sequenced, generating ~ 30–100 nt reads for each 
3′NT-seq sample (LW1 and its corresponding HW1; LW2 
and its corresponding HW2). A total of 780 million reads 
were sequenced, 101 million of which mapped uniquely 
(i.e., after removing multi-mapped reads and potential 
PCR duplicates) to the Drosophila genome (Dm6) after 
additional filtering steps.
a b
c d
Fig. 4 Knockdown of PARP1 induces dynamic changes in the occupancy of histone marks. The occupancy of activating histone marks (H3K4me3; 
lower panels of a, b) at AKAP200 (a) and CAPER (b), and the occupancy of the repressive histone marks (H3K27me3) at AKAP200 (c) and CAPER (d) 
were evaluated by ChIP‑qPCR for PARP1 target genes. All experiments were performed in triplicate, and results are presented as mean ± SD (p 
value < 0.05). Statistical significance was tested by Student’s t test method
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In 3′NT-seq experiments, the sequenced read den-
sity reflects the abundance of the transcript and the 3′ 
ends of the nascent mRNAs map the RNAPII position 
at nucleotide resolution. Thus, assuming there is no deg-
radation, these sequenced RNAs would have the cap-
tured 3′ ends of the elongating polymerase just before 
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transcription elongation inhibition by alpha-amanitin. In 
fact, the resolution afforded by 3′NT-seq and the cover-
age obtained should provide an in-depth view of genome-
wide transcriptional activity. Thus, to begin our analyses, 
we first compared the reproducibility of the biological 
replicates using the multiBamSummary tool from Deep-
Tools 2.0 [37]. The biological replicate libraries show 
strong agreement (Pearson’s coefficient > 0.988), which 
documents the robustness of our approach. We then 
compared the sequencing reads normalized by reads per 
kilobase of transcript, per million mapped reads (RPKM) 
between WT and PARP1 KD cells. To determine if tran-
scription of specific segments of mRNA genes is targeted 
by PARP1, we calculated the number of normalized reads 
for all mRNA genes and divided them into five separate 
regions: 1000 bases immediately upstream of the start 
codon (upstream); transcript (from transcription start 
sites (TSS) to transcription end sites); first 100  bp of 
the transcript; last 100 bases of the transcript; and 1000 
bases downstream of the transcript end (downstream).
A total of 100 bins were created for each region. In 
the initial global test, using a cutoff of p < 0.01, subtle 
differences between WT and PARP1 KD samples were 
observed in the bins for the upstream and transcript 
regions (Additional file  1: Fig.  S8A, B). On the other 
hand, some differences were observed at downstream 
regions as well as at the early (first 100 nt) and late gene 
bodies (last 100 nt) due to PARP1 knockdown (Addi-
tional file  1: Fig.  S8C–E). Next, using the difference in 
the percentage of reads occurring in the first 50 bins, 
we filtered the differentially expressed regions into three 
groups: Group 1: genes with reads that were shortened; 
Group 2: genes with reads that were lengthened; Group 3: 
genes with reads that had differential patterns not specifi-
cally related with shortening or lengthening. This analysis 
resulted in a total of 1786 genes, of which 348 (Group 1) 
and 307 (Group 2) had lengthened and shortened tran-
scripts, respectively, in KD versus WT cells, and the rest 
were placed in Group 3. We show the top 20 shortened 
(Additional file 1: Table S1) and lengthened genes (Addi-
tional file 1: Table S2). Examples of shortened and length-
ened genes are shown in Additional file 1: Fig. S9A and B, 
respectively.
To better understand the pattern of these lengthened 
and shortened genes, we also performed metagene anal-
ysis of the 3′NT-seq at different genomic regions. We 
observed a shifting of RNAPII locations, evidenced by 
average RNAPII densities in the PARP1 KD, which were 
substantial, often decreasing (shortened) or increasing 
(lengthened) (Fig.  5b & c), when compared to the same 
sites in WT cells. In the KD condition, when transcripts 
have shortened RNAPII profiles, there is a slight shift 
in the peak of RNAPII location toward the 5′ end of the 
gene relative to WT (Fig. 5b). For lengthened genes, one 
main peak (location) of RNAPII was observed in WT 
cells. In PARP1 depleted cells, there was a decrease in 
this peak with a concurrent appearance/increase of a 
new peak located 3′ of this peak (Fig. 5c), resulting in two 
prominent peaks.
At the upstream regions, in genes with a shortened 
RNAPII profile, one peak was detected with little to no 
change in PARP1 KD cells (Additional file 1: Fig. S10A). 
As for the lengthened genes, several peaks were present. 
In cells with depleted PARP1, there was a reduction in the 
peaks at the 5′ region with a concurrent increase in the 
peaks at the 3′ end (Additional file 1: Fig. S10B). A similar 
situation occurred for the RNAPII downstream regions 
with shortened genes (Additional file  1: Fig.  S10C). On 
the other hand, slight differences were detected with 
lengthened genes, including a stronger peak emerging 
toward the 5′ of the WT RNAPII positions (Additional 
file 1: Fig. S10D). At the other gene regions, the first and 
last 100 bp gene regions, a shortened RNAPII profile can 
be seen, similar to the downstream regions (Additional 
file 1: Fig. S10E and G, respectively). With the lengthened 
genes, there seems to be a flattening and merging of the 
two RNAPII peaks in PARP1 KD cells for the RNAPII 
locations within the first and last 100  bp genic regions 
(Additional file  1: Fig.  S10F and H). According to other 
studies, a fast polymerase is typically associated with an 
overall flattening of the RNAPII profile in the termina-
tion zone replacing the clear drop-off in RNAPII density 
that occurs in WT cells. Interestingly, such a flattened 
profile has been associated with reduced pausing [38]. 
Finally, we asked whether these genes with shortened or 
lengthened transcript regions are involved in any func-
tional pathways. For this we performed gene ontology: 
biological process analysis (GO:BP) using categoryCom-
pare [39]. GO:BP analysis results showed that genes with 
a shortened RNAPII profile were significantly enriched in 
genes associated with cell processing (Fig. 5d and Addi-
tional file 1: Table S3). On the other hand, the genes with 
a lengthened RNAPII profile were significantly involved 
with organismal organization (Fig.  5d and Additional 
file 1: Table S4).
We also provide NET-seq analyses on our candidate 
genes, AKAP and CAPER. Prominent peaks of RNAPII 
density are seen at specific nucleotides or within nar-
row regions, possibly indicative of pause sites (loca-
tions where RNAPII is detected with high probability). 
For AKAP (Fig. 6a), NET-seq showed a prominent peak 
at the 5′ of the region, with more RNAPII footprints 
downstream. Of interest, in KD cells, the main 5′ peak 
is absent, with more RNAPII footprints downstream 
compared to WT. Indeed, the last nucleotide added is 
further along the gene. These results suggest that after 
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Fig. 6 Graphic representations of the RNAPII NET‑seq results at (a) AKAP and (b) CAPER. RNAPII localization signals normalized as NET‑seq read 
count signals. Blue arrows indicate the position the final nucleotide added by RNAPII, while green arrow indicates the movement of the polymerase 
(c). ‘Kinetic model’ of PARP1–chromatin binding effects on RNAPII elongation, with consequences in alternative splicing regulation. PARP1 creates 
and/or maintains a chromatin structure, which is poised for transcription elongation. This structure enables RNAPII to pause, allowing enough 
resident time for RNAPII and its associated splicing factors to recognize specific splice sites, resulting in exon inclusion. In the absence of PARP1, the 
poised state is resolved to a more active chromatin structure, thus no pausing of the fast RNAPII, resulting in exon skipping. Although this model 
can explain our results of lengthening of the transcripts after PARP1 knockdown, it does not explain shortening of transcripts after knockdown
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the PARP1-mediated block is relieved (through knock-
down of PARP1), more RNAPII was able to move down-
stream to selectively include specific exons over others 
(Fig. 6a). The situation at the CAPER gene is slightly dif-
ferent. NET-seq in KD cells shows an increase in RNAPII 
footprint within the preceding intronic region (left 
panel—Fig.  6b), and a slowing down of RNAPII around 
the proceeding exonic region located at 7,035,750  bp 
(Fig.  6b). These results of a fast RNAPII elongation at 
upstream intronic regions and slow down of RNAPII 
elongation at the proceeding exons, could explain the 
selective exon skipping seen in PARP1 KD cells (Fig. 1b). 
Additionally, these results resonate with previous studies 
showing that slowing down of RNAPII not only results 
in exon inclusion, but has been implicated in exon skip-
ping as well [40]. In summary, our analyses for specific 
genes show a clear RNAPII pausing defect (positive and 
negative) due to PARP1 depletion. Interestingly, these 
changes in RNAPII elongation occur at the same location 
of PARP1-mediated chromatin changes (Figs.  3, 4 and 
Additional file  1: Figs.  S5 and S6), thus supporting our 
hypothesis that PARP1-mediated chromatin structural 
rearrangement regulates RNAPII elongation and splicing 
decisions.
Discussion
Cotranscriptional removal of introns occurs in the vicin-
ity of other gene expression machineries, including 
RNAPII and the chromatin remodeling factors. We pre-
viously documented that PARP1 is involved in splicing 
and proposed that PARP1 might play roles both in the 
‘adaptor model’ and in the ‘kinetic model.’ Interestingly, 
these models are not mutually exclusive. We showed 
that PARP1 influences splicing, in part, through physi-
cal interactions of PARP1-bound chromatin, the spli-
ceosome, and RNA. This finding supports the ‘adaptor 
model’ of cotranscriptional splicing [5, 11]. However, the 
effect of PARP1 on RNAPII elongation in the context of 
the ‘kinetic model’ remains unclear. At the beginning of 
this study, we proposed that PARP1 might also regulate 
RNAPII elongation. This concept is not unreasonable 
considering that several studies have shown that PARP1 
influences RNAPII pausing at promoters [41], and PARP1 
has an impact on negative elongation factor (NELF [42]) 
during RNAPII elongation. We therefore hypothesized 
that PARP1-bound chromatin regulates the RNAPII 
elongation rate by maintaining a specific chromatin 
structure, thus impacting splicing decisions. In this study, 
we undertook a comprehensive investigation of the influ-
ence of PARP1 on RNA polymerase elongation and splic-
ing. Although most of this study focused on two target 
genes, our data indicate that PARP1-bound chromatin 
does influence splicing decisions. The local influence of 
chromatin was illustrated by the experiments on the two 
genes of study—AKAP and CAPER. These experiments 
showed that depending on the exon under scrutiny, a 
given chromatin factor has a variable effect favoring 
either exon inclusion or exclusion in a rather unpredict-
able manner.
Several mechanisms have been proposed to understand 
how the rate of RNAPII modulates alternative splicing. 
First, this process can occur through the phosphoryla-
tion state of the transcribing RNAPII [43] as well as the 
association of RNAPII with specific transcription factors 
[44]. Second, modulation can occur related to the effect 
of chromatin structure on the rate of elongation of the 
transcribing RNAPII, through DNA methylation [45] and 
histone modifications [12, 40, 46], which could create or 
eliminate chromatin roadblocks to elongation. The chro-
matin structure created impacts splicing decisions. For 
instance, increased nucleosome occupancy observed in 
exons compared to introns might aid in exon definition 
(reviewed in [47]) by modulating the RNAPII elongation 
rate. It is also possible that a chromatin context mediated 
by PARP1 represents a stumbling block that influences 
RNAPII elongation, thereby impacting the outcome of 
splicing.
The way that PARP1 affects the RNAPII elongation rate 
in vivo is not fully understood. It is possible that PARP1 
acts together with other chromatin factors to remodel 
the chromatin structure. This could result in opening 
up the chromatin structure to influence RNAPII move-
ment, which suggests that a certain degree of nucleosome 
remodeling is a prerequisite for, or a consequence of, 
active transcription. To investigate the role of PARP1 in 
transcriptional elongation and splicing in vivo, we meas-
ured the co-occupancy of PARP1 and RNAPII elongat-
ing polymerase (Fig. 2). PARP1-bound nucleosomes and 
RNAPII occupied similar regions in both genome-wide 
studies and in gene-specific loci.
We next determined the structure of the chromatin 
bound by PARP1 (Figs. 3, 4 and Additional file 1: Figs. S5 
and S6). The nucleosomes bound by PARP1 had both 
activating and repressive marks within these two genes. 
Typically, the combination of repressive and activat-
ing histone marks at promoters, keeps genes expressed 
at low levels but poised for rapid activation. Addition-
ally, RNAPII pause sites in transcription elongation 
often correlate with positioned nucleosomes [28, 35], 
and these nucleosomes are marked by bivalent histone 
marks. Thus, the fact that PARP1-bound nucleosomes 
within gene bodies displayed both activating and repres-
sive marks indicated that this is a transcriptionally poised 
region. Most likely, PARP1-bound chromatin has cre-
ated a paused region for transcriptional elongation. We 
posit these results are instigated directly by PARP1, as 
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two siRNAs targeting different regions of PARP1 showed 
similar results, while PARylation inhibition had no effect 
producing results comparable to WT cells (Figs. 3, 4 and 
Additional file  1: Figs.  S5 and S6). In fact, once PARP1 
was depleted, the remodeling of chromatin structure to 
a more open chromatin structure via differential nucleo-
some occupancy/positioning, and histone modifications, 
would allow for transcriptional elongation (Fig. 3). Thus, 
our results showing bivalency at PARP1-occupied sites 
suggest these are sites of paused transcription, poised for 
activation. Another epigenetic mark related to alterna-
tive splicing regulation is DNA methylation. Though we 
analyzed possible differential DNA methylation changes 
at these sites (data not shown), the results were diffi-
cult to interpret. We attribute this difficulty to the lack 
and//or very low levels of DNA methylation present 
in the fly genome [48]. Overall, our data are consistent 
with the idea that a chromatin structure mediated by 
PARP1, impacts RNAPII elongation and possibly splicing 
decisions.
The effect of PARP1 on polymerase elongation and 
pausing has been shown in several previous studies. For 
instance, at heat shock promoters, immediately after 
induction, PARP1 mediates a rapid loss of nucleosomes 
in the bodies of induced Hsp70 genes, indicating that 
PARP1 acted as a block to transcription elongation. 
Immediately after the block is released through PARyla-
tion of PARP1 and histones, nucleosomes are remod-
eled, allowing for polymerase to move along the gene 
body with consequences in increased transcript levels 
[27, 41, 49]. Interestingly, another study showed that 
PARP1 PARylates and inhibits negative elongation fac-
tor (NELF), thus illustrating that PARP1 is important in 
transcription elongation. The latter study further showed 
that knockdown of PARP1 or inhibition of its PARylation 
activity, increased RNAPII pausing and reduced pro-
ductive elongation [42]. These studies therefore provide 
functional links between PARP-1, ADP-ribosylation, and 
NELF. Furthermore, the binding of PARP1 to nascent 
RNA was shown to reduce the rate of RNA elongation 
by RNAPII, and subsequent automodification of PARP1 
removes the transcriptionally inhibitory PARP1 mol-
ecules, thus up-regulating RNA synthesis [50]. Together, 
these studies suggest a link between PARP1 and RNAPII 
elongation and likely suggest that PARP1 initially would 
act as a “bump” to elongating RNAPII. With subsequent 
signals, PARP1 gets PARylated, releasing the block to 
transcription. PARP1 therefore could act as a hinge 
between signaling pathways and gene expression by com-
municating with the direct regulators of pausing [41, 
42, 49]. Our data are consistent with the above studies. 
First, we observed that Pro-seq signals of paused RNAPII 
are in the same vicinity as PARP1-bound nucleosomes 
genome-wide (Additional file 1: Fig. S3). Sometimes the 
RNAPII signal is shifted a little downstream (Additional 
file  1: Fig.  S3B–D), and the peak becomes broader with 
some tailing when compared to the PARP binding peak. 
These results hinted to the possibility that PARP1-bound 
nucleosomes could be involved in RNAPII elongation 
kinetics and possibly that some RNAPII backtracking 
occurs at these nucleosomes. RNAPII backtracking has 
been suggested to be the rate-limiting step in RNAPII 
elongation kinetics [35]. Although we could not defini-
tively show RNAPII backtracking in this study, our 
results demonstrate a correlative presence of PARP1 
nucleosome and RNAPII peaks within the gene body. 
Interestingly, knockdown of PARP1 resulted in loss of 
PARP1 signals at target regions with a corresponding loss 
of RNAPII signals (Fig.  2 and Additional file  1: Figs.  S5 
and S6), suggesting that loss of PARP-1 is necessary to 
achieve an efficient relieve from the elongation block of 
RNAPII into productive elongation.
However, these low-resolution studies do not provide 
a detailed understanding of kinetic coupling for the elon-
gation rate, pausing, and nascent RNA structure. We 
therefore used a modified version of native elongating 
transcript sequencing (NET-seq), combining NET-seq 
[36] and 3′NT-seq [35] protocols. Although 3′NT maps 
all forms of RNAPII (paused, backtracked, and recover-
ing), it does not map initiating RNAPII. Thus, all our sub-
sequent analyses focused on the regions mapping to the 
body of the transcripts, as well as upstream and down-
stream of the TSS. Our analyses mapping the impact of 
PARP1 on the RNAPII location showed that some of the 
transcripts were lengthened after PARP1 knockdown 
while others were shortened. In comparing our NET-
Seq data with our previous study on alternative splicing 
detected with PARP1-KD RNA-Seq [5] using rMATS 
[51], transcripts with shortened sites have twice as many 
alternative splice events than those with lengthened sites 
or with sites with no change, providing further evidence 
that pausing affects alternative splice mechanisms (see 
Additional file 2).
Based on our data, we propose a model whereby PARP1 
mediates a chromatin structure (nucleosome remod-
eling and differential occupancies of histone marks) that 
slows down the rate of RNAPII elongation, resulting in 
enough resident time for RNAPII (Ser2P) and its associ-
ated splicing factors to recognize weak splice sites. And 
in the absence of PARP1, a more open chromatin struc-
ture ensues, allowing fast RNAPII elongation resulting 
in exon skipping (Fig. 6c). This model resonates with our 
results showing that after PARP1 knockdown, there is a 
loss of PARP1-RNAPII co-occupancy (fast RNAPII elon-
gation) with consequences in exon skipping. In some 
cases though, we observed shortening of transcripts after 
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PARP1 knockdown, indicative of a slowing down of poly-
merase elongation. Our model though cannot explain 
these instances of slow RNAPII and exon skipping in the 
absence of PARP1. Thus, further studies will be needed 
to tease how PARP1-bound chromatin, by slowing down 
the rate of RNAPII elongation, also results in exon exclu-
sion. Generally, the ‘kinetic model’ of RNAPII’s effect on 
splicing decisions states that ‘slow RNAPII’ yields exons 
that are included while ‘fast RNAPII’ leads to exon skip-
ping. However, contrary to this simplistic interpretation 
of the kinetic model, our results show that PARP1–chro-
matin binding instigates both lengthening and shorten-
ing of transcripts. We therefore interpret this effect of 
PARP1 on RNAPII elongation and splicing to be context 
specific. This interpretation is supported by our recent 
studies where we observed both exon inclusion and 
exon skipping after PARP1 depletion/PARylation inhibi-
tion [5, 11]. In addition, several studies that focused on 
the kinetic coupling of splicing and transcription showed 
that similar elongation changes promote different splic-
ing outcomes [43, 52, 53]. Thus, changing the elongation 
rate may not alter the window of opportunity for positive 
splicing factors to bind but may also allow negative splic-
ing factors to bind, justifying why slow RNAPII elonga-
tion can also favor exon skipping.
Conclusions
We observed that PARP1 depletion produces skipping of 
exons on the AKAP and CAPER genes. RNAPII accumu-
lated at the alternative exons of these genes, which are 
potential pause sites that facilitate changes in splicing 
[28, 54, 55]. Upon PARP1 depletion, we showed changes 
in alternative splicing events and RNAPII accumulation, 
suggesting that a correct chromatin structure is required 
for the normal splicing events taking place at these alter-
native exons. The salient question is, why is this region so 
sensitive to PARP1 depletion? We analyzed the context of 
PARP1 occupying this region (Figs. 3, 4; Additional file 1: 
Figs. S5 and S6). In the presence of PARP1, both activat-
ing and repressive histone marks are also present in this 
region. In addition to RNAPII elongation rate, PARP1-
bound chromatin may also play a role in recruiting splic-
ing factors. Because PARP1 can post-translationally 
modify histones [56, 57], it is possible that the absence 
of a correct nucleosomal structure under conditions of 
PARP1 depletion might also impair the recruitment of 
these splicing factors to the chromatin. Whatever the 
case, our data show a link in PARP1 depletion, RNAPII 
phosphorylation state, RNAPII elongation state, histone 
modification, and nucleosome positioning. In summary, 
the results in this study are consistent with the idea that 
PARP1 is crucial in gene regulatory processes in the cell.
Materials
1. S2 cell culture and siRNA-mediated knockdown
Drosophila melanogaster S2 cells (obtained from 
Thermo Fisher Scientific, Waltham, MA 02451) were 
cultured in Schneider’s Drosophila medium (Life Tech-
nologies, Austin, TX 78744) supplemented with 10% 
heat-activated fetal bovine serum (Sigma, St Louis, MO 
63146), 100 U/ml penicillin, and 100  μg/ml streptomy-
cin at 25 °C. All experimental samples and controls were 
growth time and cell-density matched. siRNA-mediated 
PARP1 knockdown was performed as described previ-
ously [5]. siRNA1 for KD1 was made according to the 
Lis laboratory—Cornell University, Ithaca, NY, USA [49], 
while siRNA2 was made from PCR products targeting 
specific exons of PARP1 and LacZ were obtained from 
the Drosophila RNAi Screening Center (FlyRNAi.org—
the database of the Drosophila RNAi screening center: 
2012 update) to produce double-stranded RNA (dsRNA) 
for PARP1 knockdown and non-targeting control LacZ. 
Depletion of PARP1 was confirmed by Western blot and 
quantitative PCR using primers 1–4 (Additional file  1: 
Table S5).
2. PARylation inhibition
Cells were treated with 10  μM PJ34 hydrochloride 
(PARylation inhibitor, Thermo Fisher Scientific, #528150, 
Rockford, IL, 61101) or vehicle overnight for 16 h. Cells 
were then washed twice with PJ34-free medium, pelleted, 
and frozen for experiments.
3. Western blots
Western blots were performed using a standard pro-
tocol, and input dilutions were used as a quantitative 
indication of signal linearity. Protein samples were re-
suspended in SDS loading buffer and electrophoresed 
on a 10% Tris–glycine gel with Tris running buffer. The 
proteins were transferred to PVDF membrane (Thermo 
Scientific, Rockford IL, 61101) and sequentially probed 
with primary antibodies for PARP1 and actin. Western 
blot-based detection was performed using alkaline phos-
phatase-coupled secondary antibodies (Sigma, St Louis, 
MO 63146) with Amersham ECF substrate for visualiza-
tion (GE Healthcare, Waukesha, WI 53188), and images 
were obtained using Typhoon FLA 9500 (GE Healthcare, 
Piscataway, NJ 08854). ImageQuant TL software was 
used to quantify protein signals.
4. Measurement of poly-ADP-ribose (PAR) level
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PAR assay in cellular extract was done using high-
throughput chemiluminescent ELISA (HT PARP in vivo 
Pharmacodynamic Assay II kit from Trevigen, #4520-
096-K, Gaithersburg, MD 20877). Net mean relative light 
units (RLU) values of the PAR standards were calculat-
ing by subtraction of the background (without PAR) from 
RLU values and presented as a function of PAR values 
(pg/ml).
5. Chromatin immunoprecipitation (ChIP)
Cross-link chromatin immunoprecipitation (X-ChIP) 
protocol was performed with slight modifications. In 
brief, 1 × 107 cells were re-suspended in PBS and fixed 
with 1% formaldehyde for 10  min. Next, cells were 
washed 3 times with cold PBS and pelleted at 1200 rpm. 
The cell pellet was re-suspended in lysis buffer (50 mM 
HEPES–KOH (pH 7.5); 140 mM NaCl; 1 mM EDTA (pH 
8); 1% SDS; 1% Triton X-100; 0.1% sodium deoxycho-
late and protease inhibitors). After 10  min incubation 
on ice, the lysate was sonicated for 20 min (30 s on/30 s 
off) with Bioruptor 300, (Diagenode, Sparta, NJ 07871) 
to shear DNA to an average fragment size of 150–700 bp. 
Cell debris was pelleted and the supernatant (contain-
ing chromatin) was used for immunoprecipitation 
(IP)—25 μg of chromatin was used in an IP experiment. 
Lysates containing chromatin were diluted 1:10 in RIPA 
buffer (50  mM  mM Tris–HCl, (pH 8); 150  mM NaCl; 
2 mM EDTA (pH 8); 1% NP-40; 0.1% SDS; 0.5% sodium 
deoxycholate and protease inhibitors), and 50 μl of chro-
matin was removed to serve as input. Primary antibodies 
(PARP1, S2P, 4H8, 8WG16, H3K4me3, and H3K27me3) 
were added to the samples (10  μg per 25  μg DNA) and 
rotated at 4 °C for 1 h. Rabbit IgG was used for negative 
or non-specific background control. The pre-bound anti-
body–chromatin complexes were incubated with Protein 
A/G Dynabeads (Thermo Fisher Scientific, Waltham, MA 
02451) overnight at 4 °C with rotation in the presence of 
BSA (0.2 mg/ml). Using a magnetic stand for separation, 
all beads were washed twice with low salt buffer (0.1% 
SDS; 1% Triton X-100; 2  mM EDTA; 20  mM Tris–HCl 
(pH 8); 150 mM NaCl), then twice with high salt buffer 
(0.1% SDS; 1% Triton X-100; 2 mM EDTA; 20 mM Tris–
HCl (pH 8); 500  mM NaCl). In addition, samples were 
washed twice with LiCl buffer [0.25  M LiCl; 1% NP-40; 
1% sodium deoxycholate; 1 mM EDTA; 10 mM Tris–HCl 
(pH 8)]. Finally, specific DNA–protein complexes were 
eluted with 120  μl of elution buffer (1% SDS; 10  mM 
 NaHCO3) for 15 min at 30  °C. The immunoprecipitated 
material and chromatin input were subjected to reverse 
cross-links according to Abcam X-ChIP protocol, and 
DNA was purified using the QIAquick PCR Purifica-
tion Kit (Qiagen, Gaithersburg, MD 20878). Quantitative 
real-time PCR with primers 5–6, 9–10, 13–16, 43–44 
(intron 4–5), 77–78 (intron 3–4) (Additional file  1: 
Table S5) was used to identify the level of specific DNA 
fragments from the immunoprecipitated DNA. All sets 
of primers were designed using Integrated DNA Tech-
nologies Primer Tools. Real-time, quantitative PCR (RT-
qPCR) analysis was performed using CFX96 Real-Time 
System (Bio-Rad) with Taq DNA polymerase (MB042-
EUT-10000, Syd Labs, Natick, MA 01760) and EvaGreen 
dye (Biotium). Reactions were performed at 25  μl and 
cycling parameters are as follows: 4  min at 94  °C, fol-
lowed by 40 cycles of 45 s at 94 °C, 30 s at 60 °C and 60 s 
at 72  °C. For quality control purposes, melting curves 
for all samples were acquired (10  s at 95  °C and 60  s at 
60 °C). For qPCR analysis, fold enrichment was measured 
against the IgG negative control and values were normal-
ized to ChIP input.
6. Antibodies
For Western blot analysis:
Primary antibodies: PARP1 C terminal, rabbit (#39561, 
Active Motif, Carlsbad, CA 92008); Actin, mouse mono-
clonal (MA1-744, Thermo Fisher Scientific, Waltham, 
MA 02451). Secondary antibodies: anti-rabbit and anti-
mouse IgG (whole molecule); alkaline phosphatase anti-
body (Sigma).
For ChIP:
PARP1, rabbit (#39561, Active Motif, Carlsbad, 
CA 92008); H5 (S2P), mouse monoclonal (ab24758, 
Abcam, Cambridge, MA 02139); 4H8 mouse monoclo-
nal (ab5408, Abcam, Cambridge, MA 02139); 8WG16, 
mouse monoclonal (ab817, Abcam, Cambridge, MA 
02139); H3K4me3, mouse monoclonal (ab1012, Abcam, 
Cambridge, MA, USA 02139); H3K27me3, mouse mon-
oclonal (ab6147, Abcam, Cambridge, MA 02139), and 
for non-specificity control: Rabbit IgG (I8140; Sigma-
Aldrich, St Louis, MO 63146).
7. PCR to measure isoform expression
Total RNAs were isolated from each sample using the 
RNeasy Plus Mini kit from Qiagen (Gaithersburg, MD 
20878). 1  μg of RNA per reaction was used for reverse 
transcription reaction using iScript reverse transcriptase 
(Bio-Rad Laboratories, Hercules, CA 94547). The result-
ant cDNAs were used in PCR (S1000 Thermal Cycler, 
Bio-Rad) with the indicated primer sets (Additional file 1: 
Table S5: primers 5, 8, 9 and 12). PCR cycling parameters 
were as described in the Chromatin Immunoprecipitation 
section. PCR products were analyzed on 3.3% NuSieve 
agarose gel (Lonza, Rockland,  ME  04841) with GelStar 
Nucleic Acid Gel Stain (Lonza, Rockland, ME, 04841) 
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and visualized with Typhoon FLA 9500 (GE Healthcare, 
Piscataway, NJ 08854). ImageQuant TL software was 
used to quantify cDNA signals and calculate relative iso-
form expression. Splice isoforms were confirmed by clon-
ing the products from PCR analyses using PCR Cloning 
Kit (NEB) according to the manufacturer’s protocol and 
sequenced by Eurofins Scientific.
8. Micrococcal (MNase) digestion of chromatin and 
DNA purification
Chromatin was digested at 27 °C using a predetermined 
concentration of MNase (Sigma-Aldrich). Digestion was 
stopped by adding 1/10th the volume of stop solution 
[10% of SDS and 0.5  mM EDTA (pH 8)]. Samples were 
further digested with RNAse A (Goldbio) and proteinase 
K (Sigma-Aldrich) to remove contaminating RNAs and 
proteins. DNA was finally purified as described in the 
Chromatin Immunoprecipitation section.
9. Nucleosome scanning analysis
The resulting purified DNA samples from MNase 
digestion were electrophoretically separated on 3.5% 
NuSieve agarose gel (Lonza), and mononucleosome-
sized (140–200 bp) fragments were excised from the gel 
and purified using QIAquick PCR purification kit (Qia-
gen). Obtained DNA was analyzed using a ‘nucleosome 
walking’ technique. A set of overlapping primer pairs, 
each of which generate 100–120  bp PCR products that 
are located 20–40 bp away from neighboring primer pairs 
(Additional file 1: Table S5, primers 17–84), was used to 
analyze nucleosome positions. For every primer pair, 
the real-time PCR results (both of DNA isolated from 
nucleosomes and of naked DNA digested by micrococcal 
nuclease) were placed on a quantitative scale by compari-
son to serial dilutions of a known concentration of undi-
gested genomic DNA, used as an absolute standard.
 10. Genes of interest
AKAP200 (Flybase ID: FBgn0027932, symbol: 
CG13388)
CAPER (Flybase ID: FBgn0031883, symbol: CG11266)
 11. Net-seq 3′NT library preparation
Nascent RNA isolation was performed as described 
by Weber et  al. [35], and cap selection was done as 
described by Ya-Lin Chiu et  al. [58] using GFP-elF4E 
recombinant protein generously provided by Dr. G. 
Zentner, Indiana University. RNA:GFP-elF4E complexes 
were isolated using GFP-nAb Magnetic Agarose beads 
(Allele Biotech) according to the manufacturer’s pro-
tocol. Sequencing library preparation for nascent RNA 
samples was performed according to the Illumina Pro-
tocol with slight modifications. After 3′-SR adaptor liga-
tion, RNA was fragmented to 30–100 nucleotides with 
the RNA Fragmentation Reagent (Albion, AM8740) 
and purified according to Mayer et  al. [36]. In order to 
prevent RNA fragments ligation, we performed 3′-OH 
phosphorylation with T4 PNK (3′ phosphatase minus) 
before hybridization of reverse transcription primer and 
5′-SR adaptor ligation. After reverse transcription with 
superscript reverse transcriptase (Invitrogen), we puri-
fied cDNA on 15% polyacrylamide TBE-urea gel to avoid 
primer dimer formation, excised the gel region between 
50 and 300 nt and extracted cDNA. After PCR ampli-
fication, we performed quality control (QC) and size 
selection. To be confident, we cloned and sequenced the 
PCR products using Zero Blunt TOPO PCR Cloning kit 
(Thermo Fisher Scientific). Positive colonies were har-
vested; plasmid DNA was purified with QIAprep Spin 
Miniprep kit (Qiagen) and digested with EcoR1. Digested 
products were visualized on 1% agarose gel and sent for 
sequencing (Eurofins Scientific). After positive confir-
mation, accumulated cDNA was sent for sequencing by 
HiSeq 4000 Illumina platform. 
 12. Processing and alignment of sequencing reads
Nucleosome sequencing and analyses were done as 
in Matveeva et  al. 2016 [5]. Details on processing and 
analyses of NET-seq are found in supplementary mate-
rials and methods.
Additional files
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ing supplementary Figures 1–10 and supplementary Tables 1–6
Additional file 2. Western blot images of the full gel images found in 
Additional file 1: Supplementary Fig. S1
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